PRVB News and Press, Provention Bio Inc. From 02/17/22

Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022 PR Newswire RED BANK, N.J. , Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preven...

Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference PR Newswire RED BANK, N.J. , Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and pr...

Provention Bio Announces the Grant of Inducement Award PR Newswire RED BANK, N.J. , Feb. 4, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease...

We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk indiv...

Shares of Provention Bio (NASDAQ: PRVB) were skyrocketing 30.8% higher as of 3:41 p.m. ET on Monday. The big jump continued the momentum that began on Friday after the drugmaker announced that it intends to refile for approval of teplizumab for delaying type 1 diabetes. Some...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! The week is almost done but we’re not slacking as we check out the biggest pre-market stock movers for Friday! Source: Shutterstock Earnings reports, an investor conference, one compan...

Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA - Company to Host Conference Call Tomorrow, January 28th at 8:00 AM ET - PR Newswire RED BANK, N.J. , Ja...

Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE) - PRV-3279 is Designed to Intercept B-Cell Mediated Autoimmune Diseases - - Potential to be a Non-Depletin...

Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference PR Newswire RED BANK, N.J. , Jan. 6, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated dise...

Provention Bio (NASDAQ:PRVB) has appointed Christina Yi as Chief Operations Officer and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.  Ms. Yi most recently served as Chief Operating Officer at Vaxxinity developing vac...